Form 8-K - Current report:
SEC Accession No. 0001171843-25-001760
Filing Date
2025-03-27
Accepted
2025-03-27 07:31:09
Documents
15
Period of Report
2025-03-27
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_032725.htm   iXBRL 8-K 14686
2 PRESS RELEASE exh_991.htm EX-99.1 77574
  Complete submission text file 0001171843-25-001760.txt   303909

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE gnw-20190101.xsd EX-101.SCH 3003
4 XBRL DEFINITION FILE gnw-20190101_def.xml EX-101.DEF 25598
5 XBRL LABEL FILE gnw-20190101_lab.xml EX-101.LAB 34011
6 XBRL PRESENTATION FILE gnw-20190101_pre.xml EX-101.PRE 22139
17 EXTRACTED XBRL INSTANCE DOCUMENT f8k_032725_htm.xml XML 3312
Mailing Address 701 VETERANS CIRCLE WARMINSTER PA 18974
Business Address 701 VETERANS CIRCLE WARMINSTER PA 18974 604-419-3200
Arbutus Biopharma Corp (Filer) CIK: 0001447028 (see all company filings)

EIN.: 980597776 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34949 | Film No.: 25775308
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)